Researchers led by Yu Yamaguchi, M.D., Ph.D., have shown that in the absence of a certain protein, levels of an important carbohydrate increase to up to 40 times their usual level.

Researchers from Sanford Burnham Prebys including Evan Snyder, M.D., Ph.D., Pier Lorenzo Puri, M.D. and Alessandra Sacco, Ph.D. have received $5 million in new funding to launch a multidisciplinary stem cell training program, with an addition $10 million going to researchers at other San Diego research institutes.

As a principal investigator in the NIH's BRAIN/BICCN Initiative, Jerold Chun, M.D., Ph.D. and his team are part of a global collaboration to demystify the human brain to help better treat its diseases and disorders.

Elusive liver stem cells found ‘outside the box’ offer a ray of light to people with Alagille syndrome.

Microbes living in and on our bodies are key players in our health, and their power can be harnessed to enhance it.

The annual event provides valuable presentation experience to scientists at the beginning of their research careers.

A new grant awarded to faculty from Sanford Burnham Prebys and the Salk Institute will fund a five-year project to explore the connection between aging and liver cancer with the goal of developing new therapeutic approaches.

The Fishman Fund Awards were presented on September 23, 2021, in a virtual ceremony that honored the enduring legacy of our Institute’s founders, Dr. William and Lillian Fishman.

The grant was awarded to Marth to continue his team’s groundbreaking research on the molecular mechanisms of sepsis with the goal of achieving more effective treatments.

The three-year grant to assistant professor Karen Ocorr will study the model organisms of fruit flies and nematode worms aboard the International Space Station.

Eric Wang, Ph.D., has joined our NCI-designated Cancer Center an assistant professor in the Tumor Initiation and Maintenance Program. His lab will focus on using and developing chemical tools to influence the activity of tumor and immune cells.

The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling.